1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Streptococcal Infections - Pipeline Review, H1 2016

Streptococcal Infections - Pipeline Review, H1 2016

  • June 2016
  • -
  • Global Markets Direct
  • -
  • 78 pages

Streptococcal Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Streptococcal Infections - Pipeline Review, H1 2016’, provides an overview of the Streptococcal Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Streptococcal Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Streptococcal Infections
- The report reviews pipeline therapeutics for Streptococcal Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Streptococcal Infections therapeutics and enlists all their major and minor projects
- The report assesses Streptococcal Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Streptococcal Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Streptococcal Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Streptococcal Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Streptococcal Infections - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2

Introduction 8
Global Markets Direct Report Coverage 8
Streptococcal Infections Overview 9
Therapeutics Development 10
Pipeline Products for Streptococcal Infections - Overview 10
Pipeline Products for Streptococcal Infections - Comparative Analysis 11
Streptococcal Infections - Therapeutics under Development by Companies 12
Streptococcal Infections - Therapeutics under Investigation by Universities/Institutes 13
Streptococcal Infections - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Streptococcal Infections - Products under Development by Companies 16
Streptococcal Infections - Products under Investigation by Universities/Institutes 17
Streptococcal Infections - Companies Involved in Therapeutics Development 18
Absynth Biologics Limited 18
AstraZeneca Plc 19
Centauri Therapeutics Limited 20
ContraFect Corporation 21
Emergent BioSolutions Inc. 22
GlaxoSmithKline Plc 23
Helix BioMedix, Inc. 24
Merck and Co., Inc. 25
MGB Biopharma Limited 26
Sealife PHARMA GMBH 27
Sequoia Sciences, Inc. 28
Sumitomo Dainippon Pharma Co., Ltd. 29
Trellis Bioscience, Inc. 30
Wellstat Vaccines, LLC 31
Streptococcal Infections - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ATx-201 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
RandD Progress 41
AZ-6142 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
RandD Progress 42
CF-305 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
RandD Progress 43
EV-035 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
RandD Progress 44
firmocidin - Drug Profile 46
Product Description 46
Mechanism Of Action 46
RandD Progress 46
HB-1345 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
RandD Progress 47
J8-CRM197 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
RandD Progress 48
MGBBP-3 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
RandD Progress 49
Monoclonal Antibodies for Group A Streptococcus Infections - Drug Profile 52
Product Description 52
Mechanism Of Action 52
RandD Progress 52
Monoclonal Antibody to Inhibit Coagulase for Streptococcus Infections - Drug Profile 53
Product Description 53
Mechanism Of Action 53
RandD Progress 53
Polysaccharides for Streptococcal Infections - Drug Profile 54
Product Description 54
Mechanism Of Action 54
RandD Progress 54
SLP-0901 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
RandD Progress 55
SLP-0905 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
RandD Progress 56
SM-295291 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
RandD Progress 57
SM-369926 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
RandD Progress 58
Small Molecules for Bacterial Infections - Drug Profile 59
Product Description 59
Mechanism Of Action 59
RandD Progress 59
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 60
Product Description 60
Mechanism Of Action 60
RandD Progress 60
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 62
Product Description 62
Mechanism Of Action 62
RandD Progress 62
Streptococcus (trivalent) vaccine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
RandD Progress 63
streptococcus [serotype B] (multivalent) vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
RandD Progress 65
Streptococcus pyogenes (30-valent) vaccine - Drug Profile 66
Product Description 66
Mechanism Of Action 66
RandD Progress 66
Streptococcus pyogenes vaccine - Drug Profile 67
Product Description 67
Mechanism Of Action 67
RandD Progress 67
Streptococcus pyogenes vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
RandD Progress 68
Streptococcus pyogenes vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
RandD Progress 69
Streptococcus vaccine - Drug Profile 70
Product Description 70
Mechanism Of Action 70
RandD Progress 70
Streptococcal Infections - Dormant Projects 72
Streptococcal Infections - Discontinued Products 74
Streptococcal Infections - Product Development Milestones 75
Featured News and Press Releases 75
Aug 25, 2015: Streptococcus Vaccine Developed by UTHSC Professor of Medicine James B. Dale to Begin Clinical Trial 75
Jun 01, 2015: Researchers create new combination vaccine to fight Streptococcus A 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 77
Disclaimer 78

List of Tables
Number of Products under Development for Streptococcal Infections, H1 2016 10
Number of Products under Development for Streptococcal Infections - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Streptococcal Infections - Pipeline by Absynth Biologics Limited, H1 2016 18
Streptococcal Infections - Pipeline by AstraZeneca Plc, H1 2016 19
Streptococcal Infections - Pipeline by Centauri Therapeutics Limited, H1 2016 20
Streptococcal Infections - Pipeline by ContraFect Corporation, H1 2016 21
Streptococcal Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 22
Streptococcal Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 23
Streptococcal Infections - Pipeline by Helix BioMedix, Inc., H1 2016 24
Streptococcal Infections - Pipeline by Merck and Co., Inc., H1 2016 25
Streptococcal Infections - Pipeline by MGB Biopharma Limited, H1 2016 26
Streptococcal Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 27
Streptococcal Infections - Pipeline by Sequoia Sciences, Inc., H1 2016 28
Streptococcal Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 29
Streptococcal Infections - Pipeline by Trellis Bioscience, Inc., H1 2016 30
Streptococcal Infections - Pipeline by Wellstat Vaccines, LLC, H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Number of Products by Stage and Target, H1 2016 34
Number of Products by Stage and Mechanism of Action, H1 2016 36
Number of Products by Stage and Route of Administration, H1 2016 38
Number of Products by Stage and Molecule Type, H1 2016 40
Streptococcal Infections - Dormant Projects, H1 2016 72
Streptococcal Infections - Dormant Projects (Contd..1), H1 2016 73
Streptococcal Infections - Discontinued Products, H1 2016 74

List of Figures
Number of Products under Development for Streptococcal Infections, H1 2016 10
Number of Products under Development for Streptococcal Infections - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 32
Number of Products by Top 10 Targets, H1 2016 33
Number of Products by Stage and Top 10 Targets, H1 2016 33
Number of Products by Mechanism of Actions, H1 2016 35
Number of Products by Stage and Mechanism of Actions, H1 2016 35
Number of Products by Routes of Administration, H1 2016 37
Number of Products by Stage and Routes of Administration, H1 2016 37
Number of Products by Molecule Types, H1 2016 39
Number of Products by Stage and Molecule Types, H1 2016 39

Companies Mentioned
Absynth Biologics Limited
AstraZeneca Plc
Centauri Therapeutics Limited
ContraFect Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline Plc
Helix BioMedix, Inc.
Merck and Co., Inc.
MGB Biopharma Limited
Sealife PHARMA GMBH
Sequoia Sciences, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Trellis Bioscience, Inc.
Wellstat Vaccines, LLC

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.